- Data show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis[1]
- ADMYRA data reinforces review summarizing 90+ publications, that switching from reference …
- Two-stage strategic Transformation plan foresees measures for organizational realignment, followed by increased investments to drive growth segments
- Realignment of organization involves a planned reduction of global workforce by approximately 900 FTEs, including closure of Holzkirchen development center
HOLZKIRCHEN, May 15, 2019 – Sandoz today announces plans for a leaner and more efficient global organization, to drive cost competitiveness as the first stage of its ongoing strategic Transformation and support investments into future growth. …
- Sandoz receives generic approval for Rosuvastatin from China’s National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system
- Generic approval under China’s recently introduced QCE system is first of a kind for multinational pharmaceutical company
- Regulatory milestone demonstrates long-term strategic focus on pioneering access to high-quality medicines in world’s largest, and rapidly-growing, generics market
Holzkirchen, Germany, May 9, 2019 – Sandoz today announced that it …
- Sandoz receives generic approval for Rosuvastatin from China’s National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system
- Generic approval under China’s recently introduced QCE system is first of a kind for multinational pharmaceutical company
- Regulatory milestone demonstrates long-term strategic focus on pioneering access to high-quality medicines in world’s largest, and rapidly-growing, generics market
Holzkirchen, Germany, May 9, 2019 – Sandoz today announced that it …
- Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
- Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all markets except China and Taiwan
- Agreement is third announced biosimilars collaboration for Sandoz in 18 months; will build on robust portfolio of eight approved molecules, with a further 10-plus in development
Holzkirchen, Germany, …
- Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
- Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all markets except China and Taiwan
- Agreement is third announced biosimilars collaboration for Sandoz in 18 months; will build on robust portfolio of eight approved molecules, with a further 10-plus in development
Holzkirchen, Germany, …
- Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2]
- Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:
- Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all indications and regions
- Entresto grew to USD 357 million, +85% (cc) including the benefit from new data on hospital initiation
- Oncology sales grew 9% (cc) mainly driven by Lutathera (USD 106 million), Promacta (USD …
- Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2]
- Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:
- Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all indications and regions
- Entresto grew to USD 357 million, +85% (cc) including the benefit from new data on hospital initiation
- Oncology sales grew 9% (cc) mainly driven by Lutathera (USD 106 million), Promacta (USD …
- Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets
- Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative
- Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need
HOLZKIRCHEN, April 11 2019 – Sandoz today announces that it has …
- Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets
- Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative
- Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need
HOLZKIRCHEN, April 11 2019 – Sandoz today announces that it has …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia